Theragnostic Imaging
Group leader
Molecular imaging modalities are used for in vivo assessment of pathology, and nuclear medicine tracers can facilitate early diagnosis and evaluation of therapy response. Furthermore, molecular radionuclide therapy –using radionuclides with therapeutic instead of diagnostic properties– also allows for targeted treatment. By introducing quantitative theragnostic imaging, followed by dosimetric calculations and dose-effect evaluations, the vast potential for optimizing these treatments can be explored.
Many of the group members are also employed at the Section for Nuclear Medicine Physics, OUS, and the group collaborates closely with the Department for Nuclear Medicine in establishing novel methods and radiopharmaceuticals. The research group is responsible for quantitative measurements and advanced image analyses in various clinical studies. Furthermore, the group is conducting several projects to generate dosimetric methods for existing and novel radionuclide therapies, in order to improve the treatment regimens.
The group focuses on
- Dosimetry and treatment planning for molecular radiotherapies (theranostics)
- Quantitative PET and SPECT imaging and pharmacokinetic modelling
- Implementation of novel methods and processing techniques for nuclear medicine imaging